Definitive Contract 75A50118C00019
Award Date 9/10/18
Potential Completion Date 8/30/29
Potential Value $624M
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Corvallis, OR, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Clinger Cohen Act
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a definitive firm fixed-price contract awarded by the Joint PEO Chemical and Biological Defense agency, a subcomponent of the U.S. Department of Defense, to Siga Technologies, Inc. The $8,999,677.03 contract is for the procurement of 23,030 oral courses and 50 intravenous courses of TPOXX, an FDA-approved therapeutic medication used for treating smallpox and related viral infections. The contract has a completion date of December 31, 2024 and does not utilize any small business set-aside...
- The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a definitive firm fixed price contract valued at $7.4 million to Siga Technologies, Inc. of New York. The contract is to procure 10,000 courses of the FDA-approved smallpox therapeutic tecovirimat, also known as TPOXX, to replenish expiring stock within the Department of Defense stockpile. The solicitation was a sole source combined synopsis/solicitation for TPOXX as the only FDA-approved...
- This contract award, valued at $37,890,000, was issued by the Centers for Disease Control and Prevention (CDC) to Emergent BioDefense Operations Lansing LLC for the delivery of ACAM 2000 vaccines. ACAM 2000 is the only Food and Drug Administration (FDA)-licensed vaccine for the prevention of smallpox disease, a critical component of the U.S. government's strategic national stockpile. The contract, awarded on September 30, 2015, is a firm-fixed-price delivery order with an ultimate completion...
- <p>This is a contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to Emergent Biodefense Operations Lansing LLC, also known as Emergent Biodefense, for the maintenance of a smallpox license. The contract is a delivery order with a firm fixed price of $38,430,000.00 and a completion date of January 31, 2019. The place of performance is located in Cambridge, Massachusetts. The contract does not have a set-aside designation.</p>
- This contract modification with Emergent BioDefense Operations Lansing LLC, a for-profit limited liability company, exercises a contract line item for the delivery of 40,000 treatment courses of the oral suspension drug TEMBEXA for $17,104,200. The original contract, awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, is for research and development of a smallpox antiviral. The total potential value of the contract is $647,489,187. No...
- This is a $65,867,803.99 definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to VIR Biotechnology, Inc., a self-certified small disadvantaged business. The contract is for the development of pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness and medical countermeasures for other emerging pathogens with pandemic potential. This contract was awarded under a Broad...
- This is a federal contract award to Protein Sciences Corp, a for-profit manufacturer, by the National Institute of Allergy and Infectious Diseases (NIAID) within the Department of Health and Human Services (HHS). The $33,250.00 fixed-price level of effort contract is for the procurement of TAS::75 0885::TAS IV P55, 1MG ALIQUOT, CAT # 3005, LOT # 1032-145, with a completion date of June 25, 2010. The contract is not designated as a set-aside. Protein Sciences provides specialized pandemic...
- <p>This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Prommune Inc., a for-profit organization, to develop a human vaccine for Toxoplasma gondii. The contract has a ceiling value of $438,932.00 and is a firm fixed-price contract. The award was made on August 30, 2016, with an ultimate completion date of August 30, 2018. The contract is set aside for small businesses.</p>
- This is a $8,650,565,549.53 Firm Fixed Price definitive contract awarded to Pfizer Inc. by the Office of the Assistant Secretary for Preparedness and Response (ASPR) for the provision of COVID-19 vaccines. The contract has an ultimate completion date of May 29, 2024 and was awarded on October 1, 2022 without any set-aside designation. Pfizer, a global pharmaceutical manufacturer, is the prime contractor for this award. The contract supports the government's COVID-19 vaccine initiatives and is...
- This is a federal contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Roche Laboratories Inc. for the purchase of Tamiflu® (antiviral medication) for the Strategic National Stockpile. The contract is a definitive contract with a firm fixed price of $199,048,013.60 and does not have a set-aside designation. The contract was awarded on September 30, 2009 with a period of performance ending on September 29, 2011. Roche Laboratories Inc....